Trial Profile

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS: Open-Label Extension for Patients Completing Study 3119002

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levosimendan (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions
Acronyms REFALS-ES
Sponsors Orion

Most Recent Events

09 Mar 2023 Status has been changed to discontinued.
18 Jan 2021 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record. (Global end date: 2020-11-18)
10 Jan 2021 This trial has been completed in Belgium (Date of the global end of the trial: 18 Nov 2020).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com